Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03510208 · ClinicalTrials.gov registry record · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
A Phase 1 study of Malignant Glioma and Malignant Brain Neoplasm, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT03510208: Recruiting Phase 1 study of Malignant Glioma and Malignant Brain Neoplasm, sponsored by Stanford University.
NCT03510208 is a Phase 1 study of Malignant Glioma and Malignant Brain Neoplasm that is actively recruiting participants, run by Stanford University. The registered enrollment target is 46 participants, below the 91-participant average among 40 other Malignant Glioma trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03510208, a Phase 1 study of Malignant Glioma and Malignant Brain Neoplasm, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can attach to tumor cells and make them more visible using a special camera during surgery, which may help surgeons better distinguish tumor cells from normal brain tissue and identify small tumors that cannot be seen using current imaging methods.
Primary Outcome
Descriptive statistical analysis of subject disposition, baseline characteristics, exposure to study drug, and adverse events will be performed. Descriptive statistics for continuous data will include mean, standard deviation, median, minimum, maximum, and inter-quartile values. Frequencies and percentages will be used to summarize categorical data.
Conditions Studied
Interventions
- BIOLOGICAL Panitumumab
- DRUG Panitumumab-IRDye800
- PROCEDURE Near-Infrared Fluorescence Imaging
- DEVICE POINPOINT-IR9000
Study Locations (1)
California
- Stanford University School of Medicine - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2018-05-16 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
What NCT03510208 shows while recruiting
NCT03510208 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 91-participant average among 40 other Malignant Glioma trials with a reported enrollment target (49% lower).
The record links to 2 conditions, with Malignant Glioma appearing as the primary indexed condition, and to 4 interventions - of which Panitumumab is the first listed.
NCT03510208 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03510208 about?
NCT03510208 is a clinical study titled "Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery". The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can attach to tumor cells and make them more visible using a special camera during surgery, which may help surgeons better di...
What is the current status of trial NCT03510208?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2018-05-16. Estimated completion is 2026-05.
What conditions does trial NCT03510208 study?
This clinical trial studies the following conditions: Malignant Glioma, Malignant Brain Neoplasm.
What interventions are being tested in trial NCT03510208?
The interventions under investigation include: Panitumumab (BIOLOGICAL), Panitumumab-IRDye800 (DRUG), Near-Infrared Fluorescence Imaging (PROCEDURE), POINPOINT-IR9000 (DEVICE).
Who is sponsoring clinical trial NCT03510208?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03510208 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03510208's enrollment target sits among peer trials
46 19th of 40 higher than 22 of 40 other Malignant Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
RECRUITING · Phase 1
-
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
RECRUITING · Phase 1
-
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
RECRUITING · Phase 1
-
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
ACTIVE NOT RECRUITING · Phase 1
-
PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
- NCT04214184 · 46 participants · NA
Biomarkers of Increased Free Living Sleep Time
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI